Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $40.38

Key Points

• Oruka Therapeutics, Inc. has received an average recommendation of "Buy" from analysts, with eight analysts rating the stock as a buy and two as a strong buy.
• The average one-year price objective for the stock among brokers is $40.3750, with recent price targets including $45.00 from HC Wainwright.
• Currently, Oruka Therapeutics' shares are trading around $13.09, down 4.2%, with a 52-week range of $5.49 to $52.32.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has been given an average recommendation of "Buy" by the ten brokerages that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $40.3750.

Several brokerages have recently weighed in on ORKA. HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Wednesday, July 23rd. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. BTIG Research began coverage on shares of Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a "buy" rating for the company. Finally, Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ORKA. FMR LLC raised its stake in shares of Oruka Therapeutics by 17.7% during the fourth quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after acquiring an additional 830,000 shares in the last quarter. Fairmount Funds Management LLC increased its holdings in Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares during the period. VR Adviser LLC raised its position in Oruka Therapeutics by 6.5% during the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock valued at $63,708,000 after purchasing an additional 200,000 shares in the last quarter. RTW Investments LP lifted its holdings in shares of Oruka Therapeutics by 5.1% in the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock worth $37,726,000 after buying an additional 95,001 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Oruka Therapeutics by 4,161.2% during the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Stock Up 8.6%

NASDAQ ORKA traded up $1.21 during trading hours on Friday, hitting $15.16. 24,313 shares of the company were exchanged, compared to its average volume of 250,166. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $52.32. The stock has a 50-day moving average price of $13.16 and a 200 day moving average price of $11.46. The stock has a market cap of $567.42 million, a PE ratio of -5.39 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02. As a group, sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.